Aurion Biotech has pushed out its CEO. Swiss healthcare company Alcon last week acquired a majority interest in Aurion, a clinical-stage startup in Seattle that is developing advanced cell ...

Please provide your email address to receive an email when new articles are posted on . Aurion will operate as a separate company. The Aurion board appointed Arnaud Lacoste, PhD, as CEO.

Kratos Defense & Security Solutions has unveiled an internally funded effort to develop a hypersonic drone capable of exceeding Mach 5. Kratos is most known for its XQ-58 Valkyrie unmanned combat ...

As in many of its programs, Kratos is focusing also on the hypersonic drone’s affordability. In fact, the spokesperson added that, “Similar to Kratos Erinyes and Dark Fury Hypersonic Flyers ...

Aurion Resources (TSXV: AU) is teaming up with KoBold Metals, the mineral exploration company backed by Jeff Bezos and Bill Gates, to unlock the critical minerals potential of its Risti project in ...

Joint venture: Following satisfaction by KoBold of the earn-in requirements, a joint venture will be established with KoBold owning 75% and Aurion 25%. Net smelter returns royalty: In case an ...

Kratos is developing a hypersonic drone, adding to a growing portfolio of high-speed vehicles, CEO Eric DeMarco told Aviation Week in a March 18 interview. All further details of the project ...

Kratos Defense & Security reports quarterly earnings of 11 cents per share, which meets the analyst consensus estimate. Quarterly revenue comes in at $1.13 billion, which misses the analyst con ...

EOH = end of hole * Intervals revised with screen fire assays since original press release. Aurion drilled six new holes, totaling 959.40 m, in the Kaaresselkä area (Figures 1-4). The holes ...

“We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion’s CEO. “Don’s track record of strategic and operational financial leadership, coupled with his extensive experience as ...

A judge has ruled against investor Alcon Research on the matter of blocking investee Aurion Biotech from debuting on the public market, a decision Alcon says it will move to appeal. Cell therapy ...

Cell therapy company Aurion Biotech is moving forward with plans to IPO despite a pending lawsuit from one of its existing investors. The eye-disease-focused company plans to list on the New York ...